Physician profile
Ben L Boswell
NPI 1528316122
$4,926.66
in general payments reported to CMS, 2019-2025
19 companies · $1,303 in 2025
The $1,303 reported for 2025 was more than what 84% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $100 · 2020: $48.03 · 2021: $671 · 2022: $923 · 2023: $817 · 2024: $1,065 · 2025: $1,303.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,184.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,184.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $1,178.89 | 2020-2025 | Invega Sustenna, Invega Trinza, Spravato |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $848.33 | 2021-2025 | Caplyta |
| Neurocrine Biosciences, INC. | $839.74 | 2019-2025 | Ingrezza |
| Otsuka America Pharmaceutical, INC. | $762.25 | 2019-2025 | Abilify Maintena, Rexulti, Abilify Asimtufii |
| Alkermes, INC. | $456.45 | 2019-2025 | Aristada, Lybalvi |
| Trice Medical, INC. | $192.54 | 2025 | |
| Teva Pharmaceuticals USA, INC. | $162.68 | 2021-2025 | Uzedy, Austedo |
| Lundbeck LLC | $81.83 | 2023-2025 | Rexulti |
| Vertical Pharmaceuticals, LLC | $70.21 | 2024-2025 | Relexxii |
| Hydrocision, INC. | $50.68 | 2022 | |
| Corium, LLC | $50.10 | 2024 | Azstarys |
| Abbvie INC. | $47.30 | 2024-2025 | |
| Ironshore Pharmaceuticals INC. | $46.64 | 2024 | |
| E.R. Squibb & Sons, L.L.C. | $43.39 | 2025 | Cobenfy |
| Neuronetics, INC. | $24.51 | 2024 | Neurostar Tms Therapy System |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Collegium Pharmaceutical, INC. | $24.19 | 2025 | Jornay Pm |
| Axsome Therapeutics, INC. | $19.20 | 2024 | Auvelity |
| Allergan, INC. | $14.60 | 2019 | |
| Noven Therapeutics, LLC | $13.13 | 2024 | Xelstrym, Secuado |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ben Boswell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.